-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $25

Benzinga·07/30/2026 09:49:47
Listen to the news
BTIG analyst Mark Massaro maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and raises the price target from $24 to $25.